Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 26;11(11):2898.
doi: 10.3390/biomedicines11112898.

Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention

Yousef M Al-Saraireh  1 , Fatemah O F O Alshammari  2 , Omar H Abu-Azzam  3 , Sa'ed M Al-Dalain  1 , Yahya M Al-Sarayra  4 , Mansour Haddad  5 , Hafiz Makeen  6 , Aiman Al-Qtaitat  7   8 , Mohammad Almermesh  9 , Sameeh A Al-Sarayreh  10
Affiliations
Review

Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention

Yousef M Al-Saraireh et al. Biomedicines. .

Abstract

Over the past decade, there have been significant developments in treatment for ovarian cancer, yet the lack of targeted therapy with few side effects still represents a major issue. The cytochrome P450 (CYP) enzyme family plays a vital role in the tumorigenesis process and metabolism of drugs and has a negative impact on therapy outcomes. Gaining more insight into CYP expression is crucial to understanding the pathophysiology of ovarian cancer since many isoforms are essential to the metabolism of xenobiotics and steroid hormones, which drive the disease's development. To the best of our knowledge, no review articles have documented the intratumoral expression of CYPs and their implications in ovarian cancer. Therefore, the purpose of this review is to provide a clear understanding of differential CYP expression in ovarian cancer and its implications for the prognosis of ovarian cancer patients, together with the effects of CYP polymorphisms on chemotherapy metabolism. Finally, we discuss opportunities to exploit metabolic CYP expression for the development of novel therapeutic methods to treat ovarian cancer.

Keywords: cytochrome P450; gynecologic cancers; ovarian cancer; prodrug; prognosis; xenobiotics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The effects of CYP polymorphisms on ovarian cancer prognosis and therapy.
Figure 2
Figure 2
The effect of CYP mRNA expression on ovarian cancer survival according to the Kaplan–Meier analysis. The result is considered significant if p ≤ 0.05.
Figure 2
Figure 2
The effect of CYP mRNA expression on ovarian cancer survival according to the Kaplan–Meier analysis. The result is considered significant if p ≤ 0.05.
Figure 3
Figure 3
Correlation of CYP enzyme expression with immune infiltration of CAFs and CD8 + T-cells. Blue line indicates regression trend.
Figure 4
Figure 4
The proposed mechanism and targeted pathway for CYP-directed therapies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Matulonis U.A., Sood A.K., Fallowfield L., Howitt B.E., Sehouli J., Karlan B.Y. Ovarian cancer. Nat. Rev. Dis. Prim. 2016;2:16061. doi: 10.1038/nrdp.2016.61. - DOI - PMC - PubMed
    1. Carter J.S., Downs L.S., Jr. Ovarian Cancer Tests and Treatment. Female Patient. 2011;36:30–35. - PMC - PubMed
    1. Sneha S., Baker S.C., Green A., Storr S., Aiyappa R., Martin S., Pors K. Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. Biomedicines. 2021;9:290. doi: 10.3390/biomedicines9030290. - DOI - PMC - PubMed
    1. Lim S., Alshagga M., Ong C.E., Chieng J.Y., Pan Y. Cytochrome P450 4B1 (CYP4B1) as a target in cancer treatment. Hum. Exp. Toxicol. 2020;39:785–796. doi: 10.1177/0960327120905959. - DOI - PubMed

LinkOut - more resources